Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.
Rosenberg L, Levaux H, Levine RL, Shah A, Denmark J, Hereema N, Owen M, Kalk S, Kenny N, Vinson G, Vergilio JA, Mims A, Borate U, Blum W, Stein E, Gana TJ, Stefanos M, Yocum A, Marcus S, Shoben A, Druker B, Byrd J, Burd A. Rosenberg L, et al. Among authors: byrd j. Ther Innov Regul Sci. 2021 Sep;55(5):926-935. doi: 10.1007/s43441-021-00277-w. Epub 2021 May 16. Ther Innov Regul Sci. 2021. PMID: 33997942 Free PMC article.
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. Farag SS, et al. Among authors: byrd jc. Bone Marrow Transplant. 2005 Apr;35(7):653-61. doi: 10.1038/sj.bmt.1704867. Bone Marrow Transplant. 2005. PMID: 15711571 Clinical Trial.
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Mims A, et al. Among authors: byrd jc. Leukemia. 2013 Apr;27(4):871-8. doi: 10.1038/leu.2012.342. Epub 2012 Nov 26. Leukemia. 2013. PMID: 23178755 Free PMC article.
Antibody therapy of acute and chronic leukemias.
Cataland SR, Lucas M, Byrd JC. Cataland SR, et al. Among authors: byrd jc. Curr Pharm Biotechnol. 2001 Dec;2(4):357-67. doi: 10.2174/1389201013378608. Curr Pharm Biotechnol. 2001. PMID: 11762417 Review.
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.
Bloomfield CD, Ruppert AS, Mrózek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA; Cancer and Leukemia Group B (CALGB) Study 8461. Bloomfield CD, et al. Among authors: byrd jc. Ann Hematol. 2004;83 Suppl 1:S84-5. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124687 No abstract available.
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
Eisfeld AK, Mrózek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, Kroll KW, Blachly JS, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Eisfeld AK, et al. Among authors: byrd jc. Leukemia. 2017 Oct;31(10):2211-2218. doi: 10.1038/leu.2017.86. Epub 2017 Mar 24. Leukemia. 2017. PMID: 28321123 Free PMC article.
1,544 results